# A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance

> **NCT01018693** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** VAK694; Alutard Avanz SQ
- **DRUG:** VAK694 placebo infusion; Alutard Avanz SQ
- **DRUG:** VAK694 placebo infusion; Saline

## Key facts

- **NCT ID:** NCT01018693
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018693, "A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01018693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*